{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:06:12Z","timestamp":1791295572729,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by cortico-striatal dysfunction and loss of glutamate uptake. At 7 weeks of age, R6\/2 mice, which model an aggressive form of juvenile HD, show a glutamate-uptake deficit in striatum that can be reversed by treatment with ceftriaxone, a \u03b2-lactam antibiotic that increases GLT1 expression. Only at advanced ages (&gt; 11 weeks), however, do R6\/2 mice show an actual loss of striatal GLT1. Here, we tested whether ceftriaxone can reverse the decline in GLT1 expression that occurs in older R6\/2s.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Western blots were used to assess GLT1 expression in both striatum and cerebral cortex in R6\/2 and corresponding wild-type (WT) mice at 9 and 13 weeks of age. Mice were euthanized for immunoblotting 24 hr after five consecutive days of once daily injections (ip) of ceftriaxone (200 mg\/kg) or saline vehicle. Despite a significant GLT1 reduction in saline-treated R6\/2 mice relative to WT at 13, but not 9, weeks of age, ceftriaxone treatment increased cortical and striatal GLT1 expression relative to saline in all tested mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The ability of ceftriaxone to up-regulate GLT1 in R6\/2 mice at an age when GLT1 expression is significantly reduced suggests that the mechanism for increasing GLT1 expression is still functional. Thus, ceftriaxone could be effective in modulating glutamate transmission even in late-stage HD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1423-0127-17-62","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T18:15:04Z","timestamp":1280254504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6\/2 model of Huntington's disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Youssef","family":"Sari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V","family":"Rebec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,27]]},"reference":[{"issue":"7","key":"176_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/0166-2236(90)90111-M","volume":"13","author":"M DiFiglia","year":"1990","unstructured":"DiFiglia M: Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 1990, 13 (7): 286-289. 10.1016\/0166-2236(90)90111-M.","journal-title":"Trends Neurosci"},{"issue":"5","key":"176_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/0306-4522(81)90168-8","volume":"6","author":"F Fonnum","year":"1981","unstructured":"Fonnum F, Storm-Mathisen J, Divac I: Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience. 1981, 6 (5): 863-873. 10.1016\/0306-4522(81)90168-8.","journal-title":"Neuroscience"},{"key":"176_CR3","volume-title":"Huntington's Disease","author":"PS Harper","year":"1996","unstructured":"Harper PS: Huntington's Disease. 1996, W.B. Saunders London, 2","edition":"2"},{"issue":"5","key":"176_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0896-6273(02)00872-3","volume":"35","author":"CA Ross","year":"2002","unstructured":"Ross CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 2002, 35 (5): 819-822. 10.1016\/S0896-6273(02)00872-3.","journal-title":"Neuron"},{"issue":"Pt 8","key":"176_CR5","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/brain\/awf180","volume":"125","author":"PF Behrens","year":"2002","unstructured":"Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB: Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 2002, 125 (Pt 8): 1908-1922. 10.1093\/brain\/awf180.","journal-title":"Brain"},{"issue":"5","key":"176_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1006\/nbdi.2001.0430","volume":"8","author":"JC Lievens","year":"2001","unstructured":"Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP: Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis. 2001, 8 (5): 807-821. 10.1006\/nbdi.2001.0430.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"176_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","volume":"153","author":"BR Miller","year":"2008","unstructured":"Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV: Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6\/2 mouse. Neuroscience. 2008, 153 (1): 329-337. 10.1016\/j.neuroscience.2008.02.004.","journal-title":"Neuroscience"},{"issue":"2","key":"176_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11064-007-9463-1","volume":"33","author":"B Hassel","year":"2008","unstructured":"Hassel B, Tessler S, Faull RL, Emson PC: Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res. 2008, 33 (2): 232-237. 10.1007\/s11064-007-9463-1.","journal-title":"Neurochem Res"},{"issue":"1","key":"176_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-0082(00)00067-8","volume":"65","author":"NC Danbolt","year":"2001","unstructured":"Danbolt NC: Glutamate uptake. Prog Neurobiol. 2001, 65 (1): 1-105. 10.1016\/S0301-0082(00)00067-8.","journal-title":"Prog Neurobiol"},{"issue":"6","key":"176_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0197-0186(98)00055-2","volume":"33","author":"MB Robinson","year":"1998","unstructured":"Robinson MB: The family of sodium-dependent glutamate transporters: a focus on the GLT-1\/EAAT2 subtype. Neurochem Int. 1998, 33 (6): 479-491. 10.1016\/S0197-0186(98)00055-2.","journal-title":"Neurochem Int"},{"issue":"1","key":"176_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.nbd.2008.12.017","volume":"34","author":"AM Estrada-Sanchez","year":"2009","unstructured":"Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L: Glutamate toxicity in the striatum of the R6\/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis. 2009, 34 (1): 78-86. 10.1016\/j.nbd.2008.12.017.","journal-title":"Neurobiol Dis"},{"issue":"7021","key":"176_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","volume":"433","author":"JD Rothstein","year":"2005","unstructured":"Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005, 433 (7021): 73-77. 10.1038\/nature03180.","journal-title":"Nature"},{"issue":"5-6","key":"176_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pneurobio.2006.11.001","volume":"81","author":"C Cepeda","year":"2007","unstructured":"Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS: The corticostriatal pathway in Huntington's disease. Prog Neurobiol. 2007, 81 (5-6): 253-271. 10.1016\/j.pneurobio.2006.11.001.","journal-title":"Prog Neurobiol"},{"issue":"36","key":"176_CR14","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1523\/JNEUROSCI.2804-08.2008","volume":"28","author":"AG Walker","year":"2008","unstructured":"Walker AG, Miller BR, Fritsch JN, Barton SJ, Rebec GV: Altered information processing in the prefrontal cortex of Huntington's disease mouse models. J Neurosci. 2008, 28 (36): 8973-8982. 10.1523\/JNEUROSCI.2804-08.2008.","journal-title":"J Neurosci"},{"issue":"3","key":"176_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996, 87 (3): 493-506. 10.1016\/S0092-8674(00)81369-0.","journal-title":"Cell"},{"issue":"29","key":"176_CR16","doi-asserted-by":"publisher","first-page":"9239","DOI":"10.1523\/JNEUROSCI.1746-09.2009","volume":"29","author":"Y Sari","year":"2009","unstructured":"Sari Y, Smith KD, Ali PK, Rebec GV: Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats. J Neurosci. 2009, 29 (29): 9239-9243. 10.1523\/JNEUROSCI.1746-09.2009.","journal-title":"J Neurosci"},{"issue":"8","key":"176_CR17","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","volume":"19","author":"RJ Carter","year":"1999","unstructured":"Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ: Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 1999, 19 (8): 3248-3257.","journal-title":"J Neurosci"},{"issue":"7092","key":"176_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441 (7092): 431-436. 10.1038\/nature04870.","journal-title":"Nature"},{"issue":"19","key":"176_CR19","doi-asserted-by":"publisher","first-page":"13116","DOI":"10.1074\/jbc.M707697200","volume":"283","author":"SG Lee","year":"2008","unstructured":"Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, Volsky DJ, Fisher PB: Mechanism of ceftriaxone induction of excitatory amino Acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem. 2008, 283 (19): 13116-13123. 10.1074\/jbc.M707697200.","journal-title":"J Biol Chem"},{"issue":"5","key":"176_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.conb.2005.08.001","volume":"15","author":"K Huang","year":"2005","unstructured":"Huang K, El-Husseini A: Modulation of neuronal protein trafficking and function by palmitoylation. Curr Opin Neurobiol. 2005, 15 (5): 527-535. 10.1016\/j.conb.2005.08.001.","journal-title":"Curr Opin Neurobiol"},{"key":"176_CR21","unstructured":"Huang K, Kang MH, Askew C, Kang R, Sanders SS, Wan J, Davis NG, Hayden MR: Palmitoylation and function of Glial Glutamate Transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiology of Disease."},{"issue":"4","key":"176_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/00005072-199704000-00013","volume":"56","author":"T Arzberger","year":"1997","unstructured":"Arzberger T, Krampfl K, Leimgruber S, Weindl A: Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study. J Neuropathol Exp Neurol. 1997, 56 (4): 440-454. 10.1097\/00005072-199704000-00013.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"176_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.nbd.2005.08.014","volume":"21","author":"R Ganel","year":"2006","unstructured":"Ganel R, Ho T, Maragakis NJ, Jackson M, Steiner JP, Rothstein JD: Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol Dis. 2006, 21 (3): 556-567. 10.1016\/j.nbd.2005.08.014.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"176_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/archneur.58.3.365","volume":"58","author":"NJ Maragakis","year":"2001","unstructured":"Maragakis NJ, Rothstein JD: Glutamate transporters in neurologic disease. Arch Neurol. 2001, 58 (3): 365-370. 10.1001\/archneur.58.3.365.","journal-title":"Arch Neurol"},{"issue":"1","key":"176_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1212\/01.wnl.0000223353.34006.54","volume":"67","author":"BJ Traynor","year":"2006","unstructured":"Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME: Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006, 67 (1): 20-27. 10.1212\/01.wnl.0000223353.34006.54.","journal-title":"Neurology"},{"issue":"7","key":"176_CR26","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1128\/AAC.37.7.1518","volume":"37","author":"R Nau","year":"1993","unstructured":"Nau R, Prange HW, Muth P, Mahr G, Menck S, Kolenda H, Sorgel F: Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother. 1993, 37 (7): 1518-1524.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1423-0127-17-62.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T03:51:45Z","timestamp":1630468305000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/1423-0127-17-62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["176"],"URL":"https:\/\/doi.org\/10.1186\/1423-0127-17-62","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,27]]},"assertion":[{"value":"24 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"62"}}